Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03721679
Recruitment Status : Recruiting
First Posted : October 26, 2018
Last Update Posted : November 1, 2019
Sponsor:
Collaborators:
Chevy Chase Healthcare, Chevy Chase MD
Mt. Sinai School of Medicine, New York, New York
Bay Hematology Oncology PA, Easton MD
Information provided by (Responsible Party):
Oncovir, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 31, 2021
Estimated Study Completion Date : August 31, 2023
Publications of Results: